Lanreotide autogel

DRUG5 trials

Sponsors

Sheba Medical Center, Ipsen, Asan Medical Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions

AcromegalyCongenital HyperinsulinismGastroenteropancreatic Neuroendocrine TumorIntestinal ObstructionNeuroendocrine Tumors

Phase 2

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

CompletedNCT02275338

IpsenIntestinal Obstruction

Start: 2014-11-19End: 2017-11-09Updated: 2019-04-16

Phase 3

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

CompletedNCT04852679

IpsenGastroenteropancreatic Neuroendocrine Tumor

Start: 2021-05-24End: 2023-01-13Updated: 2024-10-01

Phase 4

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

CompletedNCT01070758

Sheba Medical CenterCongenital Hyperinsulinism

Start: 2010-02-28End: 2015-02-28Updated: 2024-04-18

Unknown Phase

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

CompletedNCT04696042

Asan Medical CenterNeuroendocrine Tumors

Start: 2021-01-01End: 2025-01-27Updated: 2025-01-28

Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

CompletedNCT06607666

Fondazione Policlinico Universitario Agostino Gemelli IRCCSAcromegaly

Start: 2023-01-26End: 2024-07-31Updated: 2024-09-23

Related Papers

Lanreotide for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in a Korean population: A multicenter prospective observational study (AIM-NETs).

Journal of Clinical Oncology2026-05-27

Efficacy and Safety of Lanreotide Autogel in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction: A Prospective Phase II Study.

2021-11-263 citations

Efficacy and safety of lanreotide 120 mg in the treatment of clinical symptoms associated with inoperable malignant intestinal obstruction (IMIO): Results from a phase II multicenter study.

Journal of Clinical Oncology2019-05-201 citations